奇正藏药
(002287)
| 流通市值：134.03亿 | | | 总市值：134.31亿 |
| 流通股本：5.30亿 | | | 总股本：5.31亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 403,015,309.71 | 2,337,969,652.39 | 1,471,754,788.04 | 1,009,833,674.27 |
| 营业收入 | 403,015,309.71 | 2,337,969,652.39 | 1,471,754,788.04 | 1,009,833,674.27 |
| 二、营业总成本 | 323,360,068.03 | 1,858,502,859.3 | 1,166,221,882.87 | 755,374,047.61 |
| 营业成本 | 74,456,695.24 | 418,374,983.28 | 270,919,592.45 | 182,875,944.63 |
| 税金及附加 | 5,653,294.77 | 39,469,702.77 | 28,084,570.42 | 21,140,550.66 |
| 销售费用 | 177,814,815.53 | 1,109,493,320.64 | 667,009,311.27 | 419,209,053.64 |
| 管理费用 | 39,629,675.49 | 170,567,074.65 | 116,005,635.93 | 75,681,829.6 |
| 研发费用 | 11,472,526.65 | 66,730,503.64 | 41,773,785.26 | 27,321,880.68 |
| 财务费用 | 14,333,060.35 | 53,867,274.32 | 42,428,987.54 | 29,144,788.4 |
| 其中:利息费用 | 14,870,045.96 | 57,787,374.57 | 45,334,350.84 | 30,276,430.26 |
| 其中:利息收入 | 1,306,883.5 | 4,185,499.95 | 3,123,839.62 | 1,264,588.13 |
| 加:公允价值变动收益 | 18,669,206.06 | 105,137,133.35 | 68,211,971.04 | 53,145,146.88 |
| 加:投资收益 | -3,334,451.19 | -4,821,968.32 | 10,696,306.85 | 4,982,971.34 |
| 资产减值损失(新) | 879,006.86 | -1,179,197.47 | -242,077.45 | -87,996.89 |
| 信用减值损失(新) | -634,789.61 | 79,678.13 | -266,855.2 | -493,889.15 |
| 其他收益 | 3,535,084.98 | 78,342,570.21 | 66,637,637.76 | 54,523,551.54 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 98,769,298.78 | 657,025,008.99 | 450,569,888.17 | 366,529,410.38 |
| 加:营业外收入 | 0.63 | 359,488.24 | 302,881.2 | 81,721.61 |
| 减:营业外支出 | 9,741,075.79 | 11,140,310.11 | 9,435,686.52 | 1,448,692.28 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 89,028,223.62 | 646,244,187.12 | 441,437,082.85 | 365,162,439.71 |
| 减:所得税费用 | 13,933,703.68 | 64,874,541.4 | 47,068,703.71 | 38,074,278.55 |
| 六、净利润 | 75,094,519.94 | 581,369,645.72 | 394,368,379.14 | 327,088,161.16 |
| 持续经营净利润 | 75,094,519.94 | 581,369,645.72 | 394,368,379.14 | 327,088,161.16 |
| 归属于母公司股东的净利润 | 75,679,793.49 | 582,281,116.79 | 393,375,922.95 | 325,685,757 |
| 少数股东损益 | -585,273.55 | -911,471.07 | 992,456.19 | 1,402,404.16 |
| (一)基本每股收益 | 0.14 | 1.1 | 0.74 | 0.61 |
| (二)稀释每股收益 | 0.14 | 1.1 | 0.74 | 0.61 |
| 八、其他综合收益 | -54,508.06 | 561,713.43 | -402,847.11 | 230,788.62 |
| 归属于母公司股东的其他综合收益 | -54,508.06 | 561,713.43 | -402,847.11 | 230,788.62 |
| 九、综合收益总额 | 75,040,011.88 | 581,931,359.15 | 393,965,532.03 | 327,318,949.78 |
| 归属于母公司股东的综合收益总额 | 75,625,285.43 | 582,842,830.22 | 392,973,075.84 | 325,916,545.62 |
| 归属于少数股东的综合收益总额 | -585,273.55 | -911,471.07 | 992,456.19 | 1,402,404.16 |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-30 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |